2. Signaling Pathways
  3. Immunology/Inflammation
  4. Nectin-4

Nectin-4

Nectin-4 is a cell adhesion molecule that plays a crucial role in cell-cell adhesion and communication. Nectin-4 is involved in various physiological processes such as embryonic development and tissue homeostasis. Nectin-4 is overexpressed on the surface of tumor cells, making it an attractive target for cancer therapy. Nectin-4 belongs to the nectin family of proteins, which is characterized by immunoglobulin-like domains and plays important roles in mediating cell-cell interactions through homophilic and heterophilic binding[1][2][3].

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P99016
    Enfortumab
    		Inhibitor 99.90%
    Enfortumab is a humanized derived anti-Nectin-4 antibody that can be conjugated with the highly efficient microtubule disruptor MMAE (HY-15162) to generate the antibody drug conjugate (ADC) Enfortumab vedotin-ejfv (HY-P99016A). Enfortumab can be used for the study of locally advanced and metastatic urothelial carcinoma.
    Enfortumab
  • HY-P99016B
    Enfortumab vedotin-ejfv (solution)
    		Inhibitor 99.78%
    Enfortumab vedotin-ejfv (solution) is an anti-Nectin-4 antibody-drug conjugate. Enfortumab vedotin-ejfv is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable maleimidocaproylvaline-citrulline linker (SGD-1006). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma.
    Enfortumab vedotin-ejfv (solution)
  • HY-P99016A
    Enfortumab vedotin-ejfv
    		Inhibitor 99.28%
    Enfortumab vedotin-ejfv is an anti-Nectin-4 antibody-drug conjugate. Enfortumab vedotin-ejfv is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable maleimidocaproylvaline-citrulline linker (SGD-1006). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma.
    Enfortumab vedotin-ejfv
  • HY-P990977
    Bulumtatug
    HY-P990977 is an Nectin-4-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001).
    Bulumtatug
Cat. No. Product Name / Synonyms Application Reactivity